Browsing Tag
Oncology
309 posts
How CLR 125 may test the limits of precision radiopharmaceutical therapy in solid tumors
Could CLR 125 redefine precision radiopharmaceutical therapy in solid tumors? Read what this means for Cellectar Biosciences, Inc. and oncology markets.
Massive Bio study shows AI clinical trial matching can work at real-world oncology scale
Massive Bio says its AI matched cancer patients to trials 4x faster in real-world practice. Read why this matters for oncology, sponsors, and care access.
Why oncology investors are watching Cogent Biosciences, Inc.’s PEAK data closely
Why investors are closely watching Cogent Biosciences’ PEAK data and what bezuclastinib could mean for valuation, revenue growth, and oncology market sentiment.
How the OptimUM-02 trial timeline may influence investor and clinical sentiment in ocular oncology
IDEAYA Biosciences nears darovasertib data. Find out how this Phase 3 readout could reshape metastatic uveal melanoma treatment today.
Amplia Therapeutics (ASX:ATX) reports five complete responses and improved survival in ACCENT pancreatic cancer trial
Amplia Therapeutics (ASX:ATX) posts 7.8% complete response rate and 11.1-month mOS in ACCENT pancreatic cancer trial. Read the full strategic analysis.
Bristol Myers Squibb (NYSE: BMY) expands Opdivo into frontline Hodgkin lymphoma, strengthening immuno-oncology leadership
Bristol Myers Squibb expands Opdivo in Hodgkin lymphoma. Discover how this reshapes treatment strategy, competition, and long-term oncology trends.
Telix Pharmaceuticals (ASX: TLX) orders four IBA cyclotrons to build in-house isotope production at RLS radiopharmacy network
Telix (ASX: TLX) orders four IBA Cyclone KIUBE cyclotrons for U.S. RLS radiopharmacy sites. What it means for isotope supply chains. Read more.
What AACR 2026 could reveal about Immunocore Holdings plc’s long-term immunotherapy durability (NASDAQ: IMCR)
Can Immunocore’s five-year KIMMTRAK data reshape oncology expectations? Discover the strategic, clinical, and investor implications now.
Avacta (AIM: AVCT) opens AVA6103 Phase 1: Can sustained-release engineering salvage exatecan’s clinical legacy?
Avacta Therapeutics opens Phase 1 enrollment for AVA6103 exatecan PDC at two US oncology centers. Early data expected H2 2026. Read what it means for AVCT investors.
VERAXA Biotech clears final shareholder hurdle as Voyager Acquisition votes yes on $1.35bn oncology de-SPAC
Voyager Acquisition shareholders approve VERAXA Biotech combination. The cancer ADC and TCE platform heads to NASDAQ as VRXA. Read the full analysis.